 Imara Inc. IMRA, a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that it will present interim data from the ongoing Phase 2a study of IMR-687 in patients with sickle cell disease at the 25th Annual European Hematology Association EHA Congress to be held virtually June 11-21, 2020. The data will be presented by Biree Andemariam, M.D., Associate Professor at UConn School of Medicine and Director of the New England Sickle Cell Institute at UConn Health, and lead investigator for the trial. Dr. Andemariams presentation Abstract S290, titled IMR-687, A Highly Selective Phosphodiesterase 9 Inhibitor PDE9I, Increases F-Cells and Fetal Hemoglobin in a Ph-2A Interim Analysis will be included in the oral abstract session, New Therapeutic Approaches for Sickle Cell Disease. 